Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Cutaneous leukocytoclastic vasculitis in a patient treated with carboplatin for uterine carcinoma
1Department of Medical Oncology, Institute of Oncology Ljubljana, 1000 Ljubljana, Slovenia
2Medical Faculty, University of Ljubljana, 1000 Ljubljana, Slovenia
3Institute of Pathology, Medical Faculty, University of Ljubljana, 1000 Ljubljana, Slovenia
DOI: 10.31083/j.ejgo.2021.01.2166 Vol.42,Issue 1,February 2021 pp.165-167
Submitted: 09 June 2020 Accepted: 19 August 2020
Published: 15 February 2021
*Corresponding Author(s): Erik Skof E-mail: eskof@onko-i.si
Cutaneous leukocytoclastic vasculitis (LCV) is a histopathological term used to refer to inflammation of the small vessels, including arterioles, capillaries and postcapillary venules, in the skin. The main morphological features of LCV are fibrinoid necrosis of the vessel wall with mainly neutrophilic infiltration and leukocytoclasis. LCV can be idiopathic or triggered by several causes, such as medications, underlying infection and malignancies. IgA vasculitis is a type of LCV with IgA-dominant immune deposits in the vascular wall. We report a rare case of skin-limited IgA vasculitis after treatment with carboplatin in a patient with uterine cancer. To our knowledge, this is the first reported case of LCV (in our case, skin-limited IgA vasculitis) connected to carboplatin treatment. A 57-year-old patient with uterine carcinoma was treated with surgery. Afterwards, she received postoperative chemotherapy with pegylated liposomal doxorubicin (PLD) in combination with carboplatin. When the disease progressed, the patient received carboplatin monotherapy; after the third round of carboplatin therapy, she developed IgA vasculitis of the skin without systemic involvement. Chemotherapy with carboplatin was discontinued. She was treated symptomatically, and after six months, the skin lesions resolved and had not reappeared as of her last visit. Carboplatin can induce LCV, and clinicians should be aware of this potential effect for the proper management of affected patients.
Vasculitis; Leukocytoclastic; Cutaneous; Carboplatin
Mirjana Rajer,Brigita Gregoric,Milanka Zivanovic,Erik Skof . Cutaneous leukocytoclastic vasculitis in a patient treated with carboplatin for uterine carcinoma. European Journal of Gynaecological Oncology. 2021. 42(1);165-167.
[1] Einhor J. Dermatologic diagnosis: leukocytoclastic vasculitis. The Permanente Journal. 2015.
[2] Quintanilha JCF, Visacri MB, Amaral LS, Lima CSP, Cintra ML, Moriel P. Leukocytoclastic vasculitis complicating cisplatin + radiation treatment for laryngeal cancer: a case report. BMC Cancer. 2017; 17: 831.
[3] Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. Journal of Clinical Oncology. 1999; 17: 409-409.
[4] Wall AE, Weaver SM, Litt JS, Rae L. Propylthiouracil-associated leukocytoclastic necrotizing cutaneous vasculitis: a case report and review of the literature. Journal of Burn Care & Research. 2017; 38: e678-e685.
[5] Yee KW, Hymes SR, Heller L, Prieto VG, Welch MA, Giles FJ. Cutaneous leukocytoclastic vasculitis in a patient with myelodys-plastic syndrome after therapy with the rapamycin analogue everolimus: case report and review of the literature. Leukemia & Lymphoma. 2006; 47: 926-929.
[6] Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology. 2010; 56: 3-23.
[7] Kuhar CG, Geršaka K, Stevanović Z, Gazićc B. Leukocytoclastic vasculitis associated with exemestane/everolimus therapy in a previously irradiated skin: case report. British Journal of Research. 2018; 5: 37.
Top